KR20200125776A - 암을 치료하기 위한 방법 및 조성물 - Google Patents

암을 치료하기 위한 방법 및 조성물 Download PDF

Info

Publication number
KR20200125776A
KR20200125776A KR1020207031218A KR20207031218A KR20200125776A KR 20200125776 A KR20200125776 A KR 20200125776A KR 1020207031218 A KR1020207031218 A KR 1020207031218A KR 20207031218 A KR20207031218 A KR 20207031218A KR 20200125776 A KR20200125776 A KR 20200125776A
Authority
KR
South Korea
Prior art keywords
day
hydroxylase
effective amount
therapeutically effective
lyase inhibitor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020207031218A
Other languages
English (en)
Korean (ko)
Inventor
알란 에이치. 아우어바크
아리 에스. 벨데그룬
Original Assignee
코우가 바이오테크놀로지, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38916904&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR20200125776(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 코우가 바이오테크놀로지, 인크. filed Critical 코우가 바이오테크놀로지, 인크.
Publication of KR20200125776A publication Critical patent/KR20200125776A/ko
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
KR1020207031218A 2006-08-25 2007-08-23 암을 치료하기 위한 방법 및 조성물 Ceased KR20200125776A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US92150606P 2006-08-25 2006-08-25
US60/921,506 2006-08-25
PCT/US2007/018769 WO2008024484A1 (en) 2006-08-25 2007-08-23 Methods and compositions for treating cancer

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020177037293A Division KR20180003636A (ko) 2006-08-25 2007-08-23 암을 치료하기 위한 방법 및 조성물

Publications (1)

Publication Number Publication Date
KR20200125776A true KR20200125776A (ko) 2020-11-04

Family

ID=38916904

Family Applications (4)

Application Number Title Priority Date Filing Date
KR1020207031218A Ceased KR20200125776A (ko) 2006-08-25 2007-08-23 암을 치료하기 위한 방법 및 조성물
KR1020097005974A Ceased KR20090059126A (ko) 2006-08-25 2007-08-23 암을 치료하기 위한 방법 및 조성물
KR1020157025243A Ceased KR20150108946A (ko) 2006-08-25 2007-08-23 암을 치료하기 위한 방법 및 조성물
KR1020177037293A Ceased KR20180003636A (ko) 2006-08-25 2007-08-23 암을 치료하기 위한 방법 및 조성물

Family Applications After (3)

Application Number Title Priority Date Filing Date
KR1020097005974A Ceased KR20090059126A (ko) 2006-08-25 2007-08-23 암을 치료하기 위한 방법 및 조성물
KR1020157025243A Ceased KR20150108946A (ko) 2006-08-25 2007-08-23 암을 치료하기 위한 방법 및 조성물
KR1020177037293A Ceased KR20180003636A (ko) 2006-08-25 2007-08-23 암을 치료하기 위한 방법 및 조성물

Country Status (20)

Country Link
EP (3) EP3804730A1 (https=)
JP (10) JP2010501575A (https=)
KR (4) KR20200125776A (https=)
CN (2) CN104306977A (https=)
AU (6) AU2007287098C1 (https=)
CA (1) CA2661422C (https=)
CY (2) CY1115477T1 (https=)
DK (2) DK2061561T3 (https=)
ES (2) ES2869343T3 (https=)
HR (2) HRP20130961T1 (https=)
HU (1) HUE054495T2 (https=)
IL (3) IL197211A0 (https=)
LT (1) LT2478907T (https=)
NO (2) NO20091190L (https=)
NZ (1) NZ597830A (https=)
PL (2) PL2061561T3 (https=)
PT (2) PT2478907T (https=)
RS (2) RS62034B1 (https=)
SI (2) SI2478907T1 (https=)
WO (1) WO2008024484A1 (https=)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3804730A1 (en) * 2006-08-25 2021-04-14 Janssen Oncology, Inc. Compositions for treating cancer
US20080051380A1 (en) 2006-08-25 2008-02-28 Auerbach Alan H Methods and compositions for treating cancer
WO2009009132A1 (en) * 2007-07-12 2009-01-15 Cougar Biotechnology, Inc. Use of 17alpha-hydroxylase/c17, 20-lyase inhibitors for the treatment of cancer
AR069079A1 (es) * 2007-10-29 2009-12-30 Takeda Pharmaceutical Farmaco para la prevencion o el tratamiento de cancer
CN102558274B (zh) * 2010-12-08 2014-10-15 深圳万乐药业有限公司 一种适合工业化生产醋酸阿比特龙的合成方法
CN102558275A (zh) * 2010-12-20 2012-07-11 天津药物研究院 α型多晶型醋酸阿比特龙结晶、其制备方法、用途和药物组合物
JP6100700B2 (ja) 2011-01-11 2017-03-22 ノバルティス アーゲー 組合せ
KR102021157B1 (ko) 2011-04-01 2019-09-11 제넨테크, 인크. Ａｋｔ 억제제 화합물 및 아비라테론의 조합물, 및 사용 방법
US20120295932A1 (en) * 2011-05-17 2012-11-22 Western Connecticut Health Network, Inc. Method for the treatment of cancer
CN103070828B (zh) * 2011-10-26 2016-01-27 山东新时代药业有限公司 一种含醋酸阿比特龙的固体分散体、片剂及其制备方法
CN102336801B (zh) * 2011-10-31 2013-05-15 南京卡文迪许生物工程技术有限公司 醋酸阿比特龙多晶型物和药用组合物
GB201207886D0 (en) * 2012-05-04 2012-06-20 Jagotec Ag Improvements in or relating to organic compounds
RU2014154009A (ru) * 2012-06-06 2016-08-10 Новартис Аг Комбинация ингибитора 17-альфа-гидроксилазы (с17,20-лиазы) и специфического ингибитора pi-3k для лечения онкологического заболевания
SG11201501870RA (en) 2012-09-26 2015-04-29 Aragon Pharmaceuticals Inc Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer
CN103800296A (zh) * 2012-11-13 2014-05-21 重庆医药工业研究院有限责任公司 一种稳定的阿比特龙口服固体药物组合物及其制备方法
SG10201907684PA (en) * 2013-01-15 2019-10-30 Aragon Pharmaceuticals Inc Androgen receptor modulator and uses thereof
US20150246060A1 (en) 2013-03-15 2015-09-03 Iceutica Inc. Abiraterone Acetate Formulation and Methods of Use
MX2015013247A (es) * 2013-03-15 2016-11-25 Iceutica Inc Formulacion de acetato de abiraterona.
BR112015025408A8 (pt) * 2013-04-04 2018-07-10 Exelixis Inc combinações de drogas para tratar câncer
US20150157646A1 (en) 2013-09-27 2015-06-11 Iceutica Inc. Abiraterone Steroid Formulation
ES3063787T3 (en) * 2013-10-01 2026-04-20 Novartis Ag Composition comprising a 17 a-hydroxylase/c17,20 lyase (cyp17a1) inhibitor and an akt inhibitor
JP6355724B2 (ja) * 2013-10-01 2018-07-11 ノバルティス アーゲー がんを治療するためのアフレセルチブと組み合わせたエンザルタミド
CN104546745A (zh) * 2013-10-14 2015-04-29 深圳海王药业有限公司 醋酸阿比特龙的片剂组合物及其制备工艺
ES2863500T3 (es) * 2015-04-10 2021-10-11 Capsugel Belgium Nv Formulaciones lipídicas de acetato de abiraterona
BR112019001398A2 (pt) 2016-07-29 2019-05-07 Janssen Pharmaceutica Nv métodos para tratamento de câncer de próstata
WO2018191141A1 (en) * 2017-04-13 2018-10-18 Janssen Pharmaceutica Nv Combination therapy for prostate cancer
AU2018351714A1 (en) 2017-10-16 2020-04-30 Aragon Pharmaceuticals, Inc. Anti-androgens for the treatment of non-metastatic castration-resistant prostate cancer
CN109718198A (zh) * 2017-10-30 2019-05-07 浙江京新药业股份有限公司 一种治疗前列腺癌的注射剂及其制备方法
JP7644713B2 (ja) * 2019-03-06 2025-03-12 プロペラ セラピューティクス インコーポレイテッド アビラテロンプロドラッグ
WO2021031991A1 (zh) * 2019-08-16 2021-02-25 中国科学院分子细胞科学卓越创新中心 治疗激素依赖性疾病及减少激素依赖性疾病患者药物耐受的组合物和方法
IL297338A (en) * 2020-04-16 2022-12-01 Tavanta Therapeutics Hungary Incorporated Methods and compositions for treating prostate cancer
CN114560903B (zh) * 2022-03-09 2023-08-01 绍兴市上虞区武汉理工大学高等研究院 一种阿比特龙衍生物的制备方法及其细胞毒性评价
LU506495B1 (en) 2024-03-01 2025-09-01 Alfasan Nederland B V 17alpha-HYDROXYLASE/17,20-LYASE (CYP17A1) INHIBITORS FOR THE TREATMENT OF SPONTANEOUS HYPERADRENOCORTICISM IN DOGS

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2265624B (en) 1992-03-31 1995-04-19 British Tech Group 17-substituted steroids useful in cancer treatment
US5604213A (en) 1992-03-31 1997-02-18 British Technology Group Limited 17-substituted steroids useful in cancer treatment
EP1276482B1 (en) * 2000-03-02 2008-01-16 University Of Pittsburgh Of The Commonwealth System Of Higher Education Combination chemotherapy
EP1351678A2 (en) * 2001-01-02 2003-10-15 Elizabeth Shanahan-Prendergast Treatment for inhibiting neoplastic lesions using incensole and/or furanogermacrens
AU2003274823A1 (en) * 2002-10-23 2004-05-13 Pantarhei Bioscience B.V. Pharmaceutical compositions comprising estetrol derivatives for use in cancer therapy
JP2006515623A (ja) * 2003-01-13 2006-06-01 セダーズ−シナイ メディカル センター 化学療法剤としてのパリカルシトール
US20060030608A1 (en) * 2004-08-04 2006-02-09 Boehringer Ingelheim Pharmaceuticals, Inc. Anti aromatase compounds pharmaceutical compositions and uses thereof
GB0418900D0 (en) * 2004-08-24 2004-09-29 Btg Int Ltd Novel salt forms
EP3804730A1 (en) 2006-08-25 2021-04-14 Janssen Oncology, Inc. Compositions for treating cancer

Also Published As

Publication number Publication date
EP3804730A1 (en) 2021-04-14
JP6445123B2 (ja) 2018-12-26
KR20090059126A (ko) 2009-06-10
LT2478907T (lt) 2021-06-25
PT2061561E (pt) 2013-10-09
WO2008024484A1 (en) 2008-02-28
PL2478907T3 (pl) 2021-10-25
EP2061561A1 (en) 2009-05-27
JP2019059750A (ja) 2019-04-18
JP6740497B2 (ja) 2020-08-12
CY1124221T1 (el) 2022-05-27
CA2661422C (en) 2017-06-27
HUE054495T2 (hu) 2021-09-28
AU2017201764A1 (en) 2017-04-06
JP2012082215A (ja) 2012-04-26
NO20091190L (no) 2009-03-20
HRP20130961T1 (hr) 2013-11-22
NZ597830A (en) 2013-02-22
NO20200775A1 (no) 2009-03-20
SI2061561T1 (sl) 2013-11-29
HK1131577A1 (en) 2010-01-29
DK2061561T3 (da) 2013-10-07
RS52956B (sr) 2014-02-28
AU2022206696A1 (en) 2022-08-11
ES2428634T3 (es) 2013-11-08
RS62034B1 (sr) 2021-07-30
JP2017052791A (ja) 2017-03-16
CN101528308A (zh) 2009-09-09
EP2478907A3 (en) 2012-08-01
JP2018065859A (ja) 2018-04-26
IL257681A (en) 2018-04-30
AU2007287098C1 (en) 2018-03-15
AU2015221447A1 (en) 2015-09-17
PL2061561T3 (pl) 2013-12-31
CY1115477T1 (el) 2017-01-04
JP2021038252A (ja) 2021-03-11
AU2007287098B2 (en) 2013-08-15
KR20180003636A (ko) 2018-01-09
JP2015110577A (ja) 2015-06-18
AU2021201649A1 (en) 2021-04-08
EP2478907A2 (en) 2012-07-25
KR20150108946A (ko) 2015-09-30
EP2478907B1 (en) 2021-04-14
AU2015221447B9 (en) 2017-07-20
JP2024164147A (ja) 2024-11-26
JP2020114851A (ja) 2020-07-30
CN104306977A (zh) 2015-01-28
JP2022185091A (ja) 2022-12-13
SI2478907T1 (sl) 2021-08-31
IL197211A0 (en) 2009-12-24
ES2869343T3 (es) 2021-10-25
DK2478907T3 (da) 2021-05-25
AU2015221447B2 (en) 2016-12-15
JP6053279B2 (ja) 2016-12-27
AU2018271331A1 (en) 2018-12-20
JP2010501575A (ja) 2010-01-21
IL227746A0 (en) 2013-09-30
HRP20210670T1 (hr) 2021-06-11
CA2661422A1 (en) 2008-02-28
PT2478907T (pt) 2021-05-26
EP2061561B1 (en) 2013-07-10
AU2007287098A1 (en) 2008-02-28

Similar Documents

Publication Publication Date Title
JP6740497B2 (ja) 癌を治療するための方法及び組成物
US10702540B2 (en) Methods and compositions for treating cancer
US11957696B2 (en) Abiraterone prodrugs
HK40120426A (zh) 阿比特龙前药
HK1173966A (en) Compositions for treating cancer

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20201028

Application number text: 1020177037293

Filing date: 20171226

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20201127

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20210705

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20220929

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20210705

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I